DHL Supply Chain’s Life Sciences and Healthcare (LSHC) sector is investing upwards of $400 million to expand its pharmaceutical and medical device distribution network footprint by 27% this year.
The expansion will add nearly 3 million additional square feet to the sector, with the ultimate goal of bringing critical healthcare products closer to trade partners and patients. DHL Supply Chain’s new investment includes the development of six new U.S. sites by the end of 2022. The investment includes costs to invest in new buildings and technology, as well as the fit-out and start-up of new or expanded operations.
“This latest investment in our Life Sciences and Healthcare sector is testament to our track record and pedigree for delivering unrivalled supply chain expertise to our partners,” says Jim Saponaro, president, Life Sciences & Healthcare, DHL Supply Chain North America. “This substantial expansion will only further deepen the connections between our customers and the patients they serve by providing best-in-class end-to-end supply chain solutions.”
The expansion will grow the list of DHL Supply Chain’s LSHC sites to 34 by the end of 2022. The new builds will be fully licensed with temperature controlled space that supports pharmaceutical storage requirements. The sites will also allow integrated solutions for both packaging and managed transportation. The LSHC sector includes warehousing, secondary packaging, managed transportation, and end-to-end supply chain management services.
(Photo courtesy of DHL)
